New targeted drug hopes to shrink Hard-to-Treat melanoma

NCT ID NCT07584226

Recruiting now Disease control Sponsor: Relay Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen May 22, 2026 · Last updated May 22, 2026

Summary

This early-stage study tests a new drug called RLY-8161 in people with advanced melanoma or other solid tumors that have a specific NRAS gene mutation. The main goals are to find a safe dose and see if the drug can shrink tumors. About 35 participants will take the drug by mouth, and researchers will monitor side effects and how the cancer responds.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NRAS G12V are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
NEXT Virginia
RECRUITING

Fairfax, Virginia, 22031, United States
START Midwest, LLC
RECRUITING

Grand Rapids, Michigan, 49546, United States

Conditions

Explore the condition pages connected to this study.

NRAS G12D NRAS G12V NRAS G13D NRAS G13R NRAS MUTATION NRAS Q61H NRAS Q61K NRAS Q61L NRAS Q61R NRAS-MUTANT ADVANCED MELANOMA NRAS-MUTANT SOLID TUMORS